PEGylated recombinant candida urate oxidase

Phase 1Protein / enzyme

SShenyang Sunshine Pharmaceutical Co., LTD.

PEGylated recombinant candida urate oxidase is one of 27 small molecule programs targeting Hyperuricemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperuricemiaActive, not recruiting

HyperuricemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Hyperuricemia

#DrugCompanyPhaseTrials

Uloric

Takeda

Approved

12 2

Farxiga

Medrol

Tekturna

Tibotec Pharmaceuticals, Ireland

Approved

1 5

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Approved

1 6

Decadron

AAspen Global Incorporated

Approved

—7

Zyloprim

Alnylam Pharmaceuticals

Phase 2

4 8

Colcrys

Alnylam Pharmaceuticals

Phase 2

3 9

Dotinurad

Eisai

Approved

1 10

Febuxostat Tab

XXuhui Central Hospital, Shanghai

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Hyperuricemia

NCT06629376

Clinical

Trials by Indication[1]

Hyperuricemia1 trial

Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1·NCT06629376·60 enrolled

Adult1 trial

A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers

Unknown status·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1·NCT04047394·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PEGylated recombinant candida urate oxidase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEGylated recombinant candida urate oxidase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEGylated recombinant candida urate oxidase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenyang Sunshine Pharmaceutical Co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 1[1]
Company: SShenyang Sunshine Pharmaceutical Co., LTD.

PEGylated recombinant candida urate oxidase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hyperuricemia1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News